TP53 and non-small cell lung carcinoma: Therefore, the transcriptional activation of IGFBP5 by FOSB might work as a pivotal molecular pathway underlying its robust anti-tumor effects and promotion of the sensitization to cisplatin in NSCLC with the genetic background of TP53-WT (Figs. 5 and 6).